The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Yao CW, Liao WC, Tu CY, Chen HJ, Teseng GC, Yeh SP

Rituximab-induced pneumonitis mimicking miliary tuberculosis.

European respiratory review : an official journal of the European Respiratory Society 2013 Dec;22;587-8 — 2013 Dec — 587-8

Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T

A case of interstitial pneumonia induced by rituximab therapy.

International journal of hematology 2005 Feb;81;169-70 — 2005 Feb — 169-70

Burton C, Kaczmarski R, Jan-Mohamed R

Interstitial pneumonitis related to rituximab therapy.

The New England journal of medicine 2003 Jun 26;348;2690-1; discussion 2690-1 — 2003 Jun 26 — 2690-1; discussion 2690-1